This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This ADRA2C antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 354-382 amino acids from the C-terminal region of human ADRA2C.
ADRA2C
Reaktivität: Human
WB, ICC, IF
Wirt: Maus
Monoclonal
S330A-80
Atto 390
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
ADRA2C
(Adrenergic, alpha-2C-, Receptor (ADRA2C))
Andere Bezeichnung
ADRA2C
Hintergrund
Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. The mouse studies revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons. The alpha2A subtype inhibited transmitter release at high stimulation frequencies, whereas the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. This gene encodes the alpha2C subtype, which contains no introns in either its coding or untranslated sequences.